Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
- Capsule
- Softgel Capsule
- Gummies
- Drop & drinks
- Tablets
- Effervescent Tablet
- Gel
- Powder
- Chewing Gum
- Pet Supplement
Veterinary raw materials
Phone: 86-18729212220
E-mail: sales@nutrition-oem.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
buy high quality Clofarabine raw powder online


Product Overview:
Clofarabine, a nucleotide analogue that combines the advantages of Fludarabine and Cladribine, inhibits both DNA polymerase and ribonucleic acid reductase, and is currently the only drug suitable for the treatment of childhood leukemia. Studies have proved that the treatment effective rate is very high, the total response rate of patients who did not respond to two conventional chemotherapy is 31%; Moreover, the patients were well tolerated and had no unpredictable adverse reactions. It has potential broad-spectrum antitumor properties.
Product Attributes
CAS:123318-82-1
MF:C10H11ClFN5O3
MW:303.68
EINECS:631-422-9
Specification: 99% min Clofarabine powder
Sample:Clofarabine powder Avaliable
Packaging:1kg/bag, 25kg/drum
Brand: Ausreson
MOQ:1KG
Appearance:white powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Product Details
What is Clofarabine?
Clofarabine is a purine nucleoside antimetabolite chemotherapy drug. It is a second-generation drug in its class, designed to improve upon and combine the positive attributes of its predecessors, Cladribine and Fludarabine, while reducing some of their toxicities.
It is classified as an antimetabolite because it mimics the natural nucleosides that are the building blocks of DNA, ultimately disrupting DNA synthesis and repair, leading to cell death.
Clofarabine Usage and Synthesis.
clofarabine, also known as clofarabine, is a new purine nucleoside anticancer drug, successfully developed by GenzymeCorporation (GenzymeCorporation, NASDAQ:GENZ), a top ten biopharmaceutical company in the United States, and its trade name is Clofarabine. On December 28, 2004, the United States Food and Drug Administration (FDA) approved clofarabine for the treatment of intractable or recurrent acute lymphoblastic leukemia in children through the fast track, which is the only drug that can be used specifically for the treatment of acute myeloid leukemia (ALL) in children. The treatment of leukemia is highly effective and well tolerated, with no unpredictable adverse reactions. It can be administered intravenously or orally, making it the first new leukemia treatment approved specifically for children in more than a decade.
Key Properties and Mechanism of Action.
-
Inhibition of DNA Synthesis: It is metabolized inside cells to an active form (clofarabine triphosphate) which gets incorporated into DNA strands. This incorporation terminates the DNA chain, preventing the DNA from elongating and thus halting cell replication.
-
Inhibition of Ribonucleotide Reductase (RNR): This is a key enzyme required for producing the DNA building blocks (deoxyribonucleotides). By inhibiting RNR, clofarabine depletes the pool of necessary components for DNA repair and synthesis.
-
Direct Induction of Apoptosis (Programmed Cell Death): Clofarabine can cause the release of pro-apoptotic factors from the mitochondria, leading directly to the programmed self-destruction of the cell, independent of its DNA-damaging effects.

Pharmacological action of Clofarabine.
Clorabine combines the advantages of Fludarabine and Cladribine to inhibit both DNA polymerase and ribonucleic acid reductase. It showed strong anticancer activity against different cell lines and tumor models. Early studies have shown that the concentration of this product below micromole can effectively inhibit the proliferation of human CNS tumors, lung cancer, kidney cancer, leukemia cells and melanoma cell lines. In vivo and in vitro experiments have shown that Crorolabine has apoptotic effect on leukemia cells. This effect is achieved by down-regulating the dephosphorization of BCL-2 group proteins BCL-X and MCL-1 and AKT. Its inhibitory effect on human leukemia cells K-562 was stronger than that of latabine and fludatrebine, with IC50 of 5nmol/L, while the IC50 of clatrebine was 16nmol/L and that of Fludatrebine was 460nmol/L. Preclinical and combination trials have shown that clofarabine and other deoxynucleotide analogues, as well as other types of anticancer agents such as etoposide, can increase the activity of deoxycytidine kinase in normal or abnormal human lymphocytes and therefore increase the anticancer efficacy.
Compre polvo crudo de Clofarabina de alta calidad en línea
Купите высококачественный сырой порошок Клофарабина онлайн
Achetez en ligne de la poudre brute de Clofarabine de haute qualité
Kaufen Sie hochwertiges Clofarabin-Rohpulver online
Compre pó bruto de Clofarabina de alta qualidade online
Inquire This Product















